Apertura Gene Therapy Launches Open Aperture, a Material Transfer Agreement Program to Facilitate Non-Commercial Access to TfR1 CapX for Academic Research…

Apertura Gene Therapy, a biotechnology company developing next-generation AAV capsids for delivering genetic medicines, today ...
Business Wire

Apertura Gene Therapy Unveils Novel Engineered AAV Capsids Targeting Human Transferrin Receptor 1 for Neurological Gene Therapy Delivery

NEW YORK--(BUSINESS WIRE)--Apertura Gene Therapy, a biotechnology company opening opportunities in genetic medicine for treating debilitating diseases with limited options, today unveiled its ...
Precision Medicine Online

Parent-Led Nonprofit Licenses Apertura's AAV Capsid for FRRS1L Gene Therapy Program

The nonprofit Finding Hope for Frizzle aims to initiate a clinical trial of the gene therapy for FRRS1L disease in the second half of 2026.
BioWorld

Apertura Gene Therapy signs FRRS1L license agreement

Nonprofit Finding Hope for Frizzle (FRRS1L) and Apertura Gene Therapy have signed a license agreement for the development of a gene therapy for FRRS1L disease, also known as early infantile epileptic ...
GEN

Depth of Field: Apertura Flashes AAV Capsids for Neurological Gene Therapy Delivery

Joseph La Barge has been mulling over the limitations of gene therapy for some time. So, when he left his position at Spark Therapeutics, having watched the company grow from its start in borrowed ...
as.com

Apertura 2025 playoff picture: Liga MX play-in matchups confirmed

It’s official: The Apertura 2025 regular season has come to a close. After 17 thrilling matchdays packed with passion and drama - right down to the final minutes - the league phase of the Apertura has ...